Literature DB >> 25600595

Aggravation of left ventricular dysfunction in patients with biopsy-proven cardiac human herpesvirus A and B infection.

F Escher1, U Kühl2, U Gross3, D Westermann4, W Poller5, C Tschöpe5, D Lassner3, H-P Schultheiss3.   

Abstract

BACKGROUND: Human herpesvirus 6 (HHV-6) A and B are lymphotropic viruses with life-long persistence, primarily associated with non-cardiac diseases, and discussed as a possible etiologic factor of myocarditis and cardiomyopathy.
OBJECTIVE: To analyze the long-term spontaneous course of cardiac patients suffering from suspected inflammatory cardiomyopathy (CMi) with persisting HHV-6 A and B infections by follow-up biopsies. STUDY
DESIGN: We prospectively evaluated patients (n=73) with biopsy-proven viral HHV-6 A and B infection in endomyocardial biopsies (EMBs), followed up by reanalysis of EMBs and left ventricular ejection fraction (LV-EF) measurements after a median period of 8.8 months (range 4-73 months). Beyond, we studied HHV-6 prevalence in isolated peripheral blood cells (PBCs) and HHV-6 species in EMBs. HHV-6 species-specific cellular infection sites within the myocardium were identified by immunohistochemistry (IHC).
RESULTS: We identified 73 patients with cardiac HHV-6 A and B persistence or newly detected in follow-up EMB (95.0% B). Proof of HHV-6 in PBCs was primarily associated with A. Persistence of cardiac HHV-6 B genome was significantly associated with cardiac dysfunction at follow-up (LV-EF deteriorated from 58.2±16.0 to 51.8±17.2%, p<0.001), and LV improvement was observed when HHV-6 B persistence resolved (LV-EF increased from 54.9±15.4 to 60.7±13.1%, p<0.001).
CONCLUSIONS: Persistence of cardiac HHV-6 B genomes was significantly associated with cardiac dysfunction, and hemodynamic parameters improved in association with HHV-6 B clearance.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  HHV6; Heart; Heart failure; Inflammatory cardiomyopathy; Prognosis

Mesh:

Year:  2014        PMID: 25600595     DOI: 10.1016/j.jcv.2014.11.026

Source DB:  PubMed          Journal:  J Clin Virol        ISSN: 1386-6532            Impact factor:   3.168


  8 in total

Review 1.  Myocarditis: A Clinical Overview.

Authors:  A L P Caforio; G Malipiero; R Marcolongo; S Iliceto
Journal:  Curr Cardiol Rep       Date:  2017-07       Impact factor: 3.955

Review 2.  Modulatory effects on dendritic cells by human herpesvirus 6.

Authors:  Rasmus Gustafsson; Mattias Svensson; Anna Fogdell-Hahn
Journal:  Front Microbiol       Date:  2015-04-30       Impact factor: 5.640

Review 3.  Viral myocarditis: a prime example for endomyocardial biopsy-guided diagnosis and therapy.

Authors:  Sophie Van Linthout; Carsten Tschöpe
Journal:  Curr Opin Cardiol       Date:  2018-05       Impact factor: 2.161

Review 4.  Cardiovascular Involvement in Chronic Hepatitis C Virus Infections - Insight from Novel Antiviral Therapies.

Authors:  Wolfgang Poller; Arash Haghikia; Mario Kasner; Ziya Kaya; Udo Bavendiek; Heiner Wedemeier; Hans-Jörg Epple; Carsten Skurk; Ulf Landmesser
Journal:  J Clin Transl Hepatol       Date:  2018-01-26

5.  Long-Term Prognosis of Suspected Myocarditis and Cardiomyopathy Associated with Viral Infection of the Myocardial Tissue: A Meta-Analysis of Cohort Studies.

Authors:  Wen-Hao Chen; You-Sheng Guo; Dong-Hui Zhang; Huan-Ji Zhang
Journal:  Cardiovasc Ther       Date:  2019-12-16       Impact factor: 3.023

6.  The Spontaneous Course of Human Herpesvirus 6 DNA-Associated Myocarditis and the Effect of Immunosuppressive Intervention.

Authors:  Ahmed Elsanhoury; Uwe Kühl; Bruno Stautner; Oliver Klein; Alexander Krannich; Daniel Morris; Monika Willner; Ewa Jankowska; Karin Klingel; Sophie Van Linthout; Carsten Tschöpe
Journal:  Viruses       Date:  2022-01-31       Impact factor: 5.818

7.  Targeted treatment in viral-associated inflammatory cardiomyopathy.

Authors:  Ahmad Amin; Sepideh Taghavi; Maryam Chenaghlou; Elahe Zare; Monireh Kamali; Nasim Naderi
Journal:  Clin Case Rep       Date:  2021-07-23

Review 8.  Cardiovascular consequences of viral infections: from COVID to other viral diseases.

Authors:  Heinz-Peter Schultheiss; Christian Baumeier; Heiko Pietsch; C-Thomas Bock; Wolfgang Poller; Felicitas Escher
Journal:  Cardiovasc Res       Date:  2021-11-22       Impact factor: 10.787

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.